Clinical Trial Evidence Informing Efficacy and Safety of Fda-Approved Treatments in Relapsed and Refractory Multiple Myeloma (RRMM) for Patients (Pts) After Quadruple-Class Exposure (Qcex)

Talvey (talquetamab-tgvs) - J&J

Tecvayli (teclistamab-cqyv) - Genmab, J&J

Carvykti (ciltacabtagene autoleucel) - J&J

Abecma (idecabtagene vicleucel) - BMS

Elrexfio (elranatamab-bcmm) - Pfizer

Larry D. Anderson, Jr., MD, PhD

Sep 11, 2026